NCT01358578

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,306 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

Conditions

• Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Placebo	Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
DRUG	secukinumab (AIN457)	secukinumab (AIN457) 150mg or 300mg subcutaneous
DRUG	etanercept	etanercept 50mg subcutaneous

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2011-05-23
• Last updated: 2021-01-05
• Results posted: 2015-09-23

Locations

152 sites across 23 countries: United States, Argentina, Australia, Belgium, Canada, Colombia, Egypt, Finland, France, Germany, Guatemala, Hungary, Iceland, India, Italy, Philippines, Poland, Romania, Singapore, South Korea, Spain, Sweden, United Kingdom